Advertisement

Topics

Novartis Aims Canakinumab At Targeted CV Patients

07:54 EST 13 Nov 2017 | SCRIP

New CANTOS analyses show that the "lower is better" mantra applies to inflammation as well as LDL-cholesterol. Novartis hope they...

      

Related Stories

 

Original Article: Novartis Aims Canakinumab At Targeted CV Patients

NEXT ARTICLE

More From BioPortfolio on "Novartis Aims Canakinumab At Targeted CV Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lipitor
Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is prescribed to lower cholesterol and triglycerides in the the...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...